In December 2024, GeneReach Biotechnology reported consolidated revenue of NT$19.49 million, representing a year-on-year increase of 6.64%. Total revenue for the year reached NT$206 million, marking an 8.41% decline compared to the previous year.

GeneReach's strategic focus on PCR diagnostic technology has begun to yield results, driving steady operational growth. In the Southeast Asian market, the African Swine Fever mobile testing vehicle initiative in Vietnam is progressing smoothly, generating consistent orders. In the Philippines, the company has actively promoted its African Swine Fever diagnostic solutions through a new distributor, receiving positive market feedback. Additionally, the Philippines has initiated the validation of the POCKIT Central testing platform, with plans to launch the platform transition project in the first half of 2025. This development is expected to inject new growth momentum into revenue.

From March 12 to 14, 2025, GeneReach will participate in the VIV Asia exhibition in Bangkok, Thailand, showcasing its comprehensive diagnostic solutions at Booth 5092 in Hall 3, underscoring the company's commitment to the Asian market.

Looking ahead to 2025, GeneReach plans to further advance its "One Health" strategy, integrating nucleic acid PCR diagnostics with next-generation sequencing (NGS) technologies to pioneer innovative applications in diagnostics. The company aims to build a cross-species pathogen monitoring network to provide comprehensive diagnostic solutions for human, animal, and environmental health. This integrated strategy not only strengthens GeneReach’s leadership in molecular diagnostics but also highlights its innovative capabilities in the global biotech market.

Resource: 東南亞布局現成效 瑞基明年營運有動能